IN-VITRO ACTIVITY OF QUINOLONES AND MACROLIDES AGAINST MYCOBACTERIA

被引:72
作者
YEW, WW
PIDDOCK, LJV
LI, MSK
LYON, D
CHAN, CY
CHENG, AFB
机构
[1] CHINESE UNIV HONG KONG,PRINCE WALES HOSP,DEPT MICROBIOL,SHA TIN,HONG KONG
[2] GRANTHAM HOSP,TB & CHEST UNIT,ABERDEEN,HONG KONG
[3] UNIV BIRMINGHAM,DEPT INFECT,BIRMINGHAM,W MIDLANDS,ENGLAND
关键词
D O I
10.1093/jac/34.3.343
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The activities of eight quinolones (ciprofloxacin, clinafloxacin, levofloxacin, oflox-acin, A-80556, sparfloxacin, temafloxacin and tosufloxacin) and three macrolides (azithromycin, clarithromycin and erythromycin) against 98 clinical isolates of Mycobacterium tuberculosis and 120 isolates of five different atypical mycobacterial species including 20 Mycobacterium kansasii, 25 Mycobacterium scrofulaceum, 25 Mycobacterium avium/intracellulare, 25 Mycobacterium chelonae and 25 Mycobacterium fortuitum were determined with the Middlebrook 7H9 broth macro-dilution method. Sparfloxacin, clinafloxacin, levofloxacin, ciprofloxacin and oflox-acin were active against M. tuberculosis (MIC90 0.06-0.5 mg/L; MBC90 0.125-2.0 mg/L). However, higher MIC90S and MBC90s of these quinolones were obtained for strains of multi-drug resistant M. tuberculosis. The macrolides tested had poor activity against M. tuberculosis isolates (MIC90 8.0 mg/L). Furthermore, high MIC90s of the quinolones and macrolides (20 to 80 mg/L) were obtained for clinical isolates of atypical mycobacteria, with the exception of clarithromycin against M. kansasii (MIC90 = 1.0 mg/L) and sparfloxacin against M. scrofulaceum (MIC90 = 1.0 mg/L). © 1994 The British Society for Antimicrobial Chemotherapy.
引用
收藏
页码:343 / 351
页数:9
相关论文
共 37 条
[11]   NEWLY DOCUMENTED ANTIMICROBIAL ACTIVITY OF QUINOLONES [J].
FURET, YX ;
PECHERE, JC .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1991, 10 (04) :249-254
[12]  
GILLESPIE S, 1992, 5TH P INT C INF DIS
[13]   MYCOBACTERIUM-AVIUM COMPLEX INFECTIONS IN PATIENTS WITH THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME [J].
HAWKINS, CC ;
GOLD, JWM ;
WHIMBEY, E ;
KIEHN, TE ;
BRANNON, P ;
CAMMARATA, R ;
BROWN, AE ;
ARMSTRONG, D .
ANNALS OF INTERNAL MEDICINE, 1986, 105 (02) :184-188
[14]   CLARITHROMYCIN MINIMAL INHIBITORY AND BACTERICIDAL CONCENTRATIONS AGAINST MYCOBACTERIUM-AVIUM [J].
HEIFETS, LB ;
LINDHOLMLEVY, PJ ;
COMSTOCK, RD .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1992, 145 (04) :856-858
[15]   THE SITE CONCENTRATIONS OF ANTIMICROBIAL AGENTS IN THE LUNG [J].
HONEYBOURNE, D ;
BALDWIN, DR .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1992, 30 (03) :249-260
[16]   INVITRO AND INVIVO ACTIVITIES OF SPARFLOXACIN (AT-4140) AGAINST MYCOBACTERIUM-TUBERCULOSIS [J].
JI, B ;
TRUFFOTPERNOT, C ;
GROSSET, J .
TUBERCLE, 1991, 72 (03) :181-186
[17]  
JI B, 1991, J ANTIMICROB CHEMOTH, V72, P181
[18]  
KAWAHARA S, 1991, Kekkaku, V66, P429
[19]   ANTI-MYCOBACTERIUM-AVIUM ACTIVITY OF QUINOLONES - IN-VITRO ACTIVITIES [J].
KLOPMAN, G ;
WANG, SM ;
JACOBS, MR ;
BAJAKSOUZIAN, S ;
EDMONDS, K ;
ELLNER, JJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (09) :1799-1806
[20]   PROSPECTIVE COMPARATIVE-STUDY OF OFLOXACIN OR ETHAMBUTOL FOR THE TREATMENT OF PULMONARY TUBERCULOSIS [J].
KOHNO, S ;
KOGA, H ;
KAKU, M ;
MAESAKI, S ;
HARA, K .
CHEST, 1992, 102 (06) :1815-1818